Beike Biotechnology

About Beike Biotechnology

Founded in July 2005, Beike Biotechnology is a Chinese high-tech enterprise specializing in the clinical transformation and technical service of biological treatment technology. With over 300 employees, more than 35% of whom are dedicated to research and development, Beike has established itself as a leader in the field of cell biology. The company's research and clinical applications in stem cell therapy began in the 1990s, with contributions from over 60 PhDs from leading Chinese universities. Many of Beike's scientists also have experience at prominent Western universities, including Stanford, the University of Minnesota, and UCLA.\n\nBeike Biotechnology operates more than 20 adult stem cell processing laboratories. In 2011, its Jiangsu Beike inspection center was accredited by the China National Accreditation Service for Conformity Assessment (CNAS), making it the first adult stem cell processing laboratory in China to receive this accreditation. This commitment to quality and safety ensures that patients receive the highest quality umbilical-cord derived adult stem cells. Since its first patient treatment in 2001, Beike has provided partner hospitals with stem cells for the treatment of over 33,500 patients. The company maintains 9 research and cell processing laboratories that adhere to GMP standards, ISO 9001, and ISO17025, and has received over US$6 million in government grants.\n\nAs a research-focused organization, Beike is dedicated to advancing cell technologies.

The company has published nearly 50 peer-reviewed research papers in scientific journals worldwide, including Nature, and has invested tens of millions in its laboratories and cell research over the past decade. Beike has a global clinical research technical support network, cooperating with over 400 domestic and foreign scientific and medical institutions to provide individualized cell preparation technologies for patients from more than 70 countries. The company holds 39 patents in the stem cell field, with 26 authorized, and has published over 100 articles in authoritative magazines. Beike has also participated in more than 60 government projects, including six at the state level.\n\nBeike Biotechnology is committed to a strict quality control system. Its adult stem cell and immune cell preparation system and Jiangsu stem cell bank have passed ISO9001 quality management system certification. The company is the first in mainland China to be a recognized member of the International Society for Cell & Gene Therapy (ISCT). Beike is also at the forefront of advanced immune cell therapy technology, with a variety of internationally advanced immunotherapy technologies and products. The company is developing an integrated cell bank and regional cell preparation center national network to create a \"cell therapy expressway network\" that meets clinical needs and provides an innovative public technology platform for the clinical transformation of cell therapy technology.

Clinic Information

Treatments Offered

Frequently Asked Questions